Related Experiment Videos
Long-term survival in primary CNS lymphoma
L E Abrey1, L M DeAngelis, J Yahalom
1Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Summary
This study on primary CNS lymphoma (PCNSL) found that combined MTX, RT, and cytarabine therapy significantly improved long-term survival, especially for younger patients. However, late toxicity and relapse remain concerns, necessitating new approaches for older individuals.
Area of Science:
- Neuro-oncology
- Clinical Oncology
- Radiation Oncology
Background:
- Primary CNS lymphoma (PCNSL) is a rare and aggressive brain tumor.
- Previous studies suggested improved outcomes with combined modality therapy.
Purpose of the Study:
- To report long-term survival and late treatment-related toxicity in patients with PCNSL treated with methotrexate (MTX), cranial radiotherapy (RT), and high-dose cytarabine.
- To evaluate prognostic factors influencing survival and toxicity.
Main Methods:
- Follow-up analysis of a cohort of 31 patients with PCNSL treated between 1986 and 1992.
- Assessment of cause-specific survival, disease-free survival, and late treatment-related toxicity.
Main Results:
- Median cause-specific survival was 42 months; 5-year survival was 22.3%, significantly better than historical controls (3-4%) treated with RT alone.
- Younger age (<50 years) was a significant prognostic factor for survival (P = .01).
- Late toxicity occurred in nearly one-third of patients, with higher risk in older patients (>60 years) (P < .0001).
Conclusions:
- Combined modality therapy for PCNSL significantly improves survival, particularly for younger patients.
- Relapse is common, and late neurologic toxicity is a significant complication.
- Development of less neurotoxic regimens is crucial for older PCNSL patients.